Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

AEGR 31.92 +0.91 (2.93%)
price chart
Aegerion Pharmaceuticals, Inc. (AEGR): Steve Cohen's Point72 Asset ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) is a $850 million market cap, biopharmaceutical company that develops therapies for patients with debilitating rare diseases.
Related articles »  
Perilous Reversal Stock: Aegerion Pharmaceuticals (AEGR)
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.
Investor Alert: Investigation of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR)  GroundReport
Stocks on the Move�Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), Sanchez ...  Techsonian (press release)
Related articles »  
Aegerion Pharmaceuticals Inc. (AEGR), Cytori Therapeutics Inc (CYTX): Scopia ...
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) continues to feel hedge funds' bullishness. Not only did Steve Cohen's Point72 Asset Management disclose an increase in its exposure to the company today, but also Matt Sirovich and Jeremy Mindich's ...
Aegerion Pharmaceuticals Given Average Recommendation of "Hold" by ...
Aegerion Pharmaceuticals (NASDAQ:AEGR) last released its earnings data on Tuesday, July 29th. The company reported ($0.33) earnings per share for the quarter, beating the analysts' consensus estimate of ($0.41) by $0.08.
Related articles »  
Bank Of America Q3 Small & Mid-Cap Biotech Preview
Below are highlights from the report with the firm's current ratings and price targets. Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) - Buy, $48 price target. "Q3 sales are key to near-term valuation, as the market has low expectations on the company's ...
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on October 1, 2014, Aegerion ...
Related articles »  
Aegerion Pharmaceuticals Inc. (AEGR) Jumps 5.28% on October 16
Aegerion Pharmaceuticals Inc. (AEGR) was among the biggest gainers on the Russell 2000 for October 16 as the stock popped 5.28% to $32.71, representing a gain of $1.64 per share.
Aegerion Pharmaceuticals (AEGR) Highlighted As Today's Perilous Reversal ...
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States.
Related articles »  
Bank of America Lowers Aegerion Pharmaceuticals to Buy (AEGR)
Aegerion Pharmaceuticals, Inc. logo Aegerion Pharmaceuticals (NASDAQ:AEGR) was downgraded by Bank of America to a �buy� rating in a research note issued on Thursday.
AEGERION (AEGR) SHAREHOLDER ALERT - Andrews & Springer LLC Is ...
... law firm focused on representing shareholders nationwide, is investigating potential securities fraud claims and breach of fiduciary duty claims against the Board of Directors of Aegerion Pharmaceuticals, Inc. AEGR, -5.20% (�Aegerion� or the ...